Proton Radiation Therapy for Lung Cancer

Presented by:
Romaine Charles Nichols, Jr., MD
Associate Professor, University of Florida Department of Radiation Oncology
UF Health Proton Therapy Institute

Faculty Disclosure:
Romaine Charles Nichols, Jr., MD, has disclosed that he has no relevant financial relationships. No one else in a position to control content has any financial relationships to disclose. Conflict of interest information for the CME Advisory Committee members can be found on the following website: All relevant financial relationships have been mitigated.

Release Date: August 19, 2021
Expiration Date:  August 19, 2022

Target Audience: This course is intended for an audience of specialty physicians, primary care physicians, physician assistants, nurses, as well as others who treat patients with lung cancer.

Learning Objectives:

As a result of participation in this activity, participants should be able to:

  1. Discuss best practices of the use of proton therapy for lung cancer based on current research.
  2. Define proton therapy and describe how proton therapy is different from conventional radiation therapy.
  3. Identify and determine the theoretical advantages to the use of proton therapy in the treatment of lung cancer.

Requirements for successful completion: Certificates are awarded upon successful completion (80% proficiency) of the post-test.

Accreditation: The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit: The University of Florida College of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Resource(s) for further study:

  1. Chang JY, Zhang X, Wang X, et al. Significant reduction of normal tissue dose by proton radiotherapy compared withthree-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer.Int J Radiat Oncol Biol Phys. Jul 15 2006;65(4):1087-1096.
  2. Nichols RC, Huh SH, Hoppe BS, et al. Protons safely allowcoverage of high-risk nodes for patients with regionally advanced non-small-cell lung cancer. Technol Cancer Res Treat.Aug 2011;10(4):317-322.
  3. Hoppe BS, Flampouri S, Henderson RH, et al. Proton therapy with concurrent chemotherapyfor non-small-cell lung cancer: technique and early results. Clin Lung Cancer. Sep 2012;13(5):352-358.
  4. Zhang X, Li Y,Pan X, et al. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulatedradiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stageIIIB non-small-cell lung cancer: a virtual clinical study. Int J Radiat Oncol Biol Phys. Jun 1 2010;77(2):357-366.
  5. ChangJY, Verma V, Li M, et al. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study. JAMA Oncol. Aug 10 2017;3(8):e172032.

[LINK TO CME VIDEO/ACTIVITY] – Will be sent a couple days after the live event.   

[LINK TO POST TEST] – Test questions will be sent closer to the date of the CME>

If you have any questions please feel free to contact Christina Mershell at or 904-831-4034.